As an established CDMO, our experts will share insight on adapting conjugation processes and analytics to non-traditional ADCs and highlight the integration of PAT into development and manufacturing. We will discuss accelerated strategies to access and solubilize drug linkers. Together, these templates and technologies will continue to help ADC developers confidently bring novel therapies to patients.
You will learn about:
Senior Scientist, Analytical Development
Melissa joined MilliporeSigma's process and analytical development team in 2018. She started her career as a fellow scientist at ORIS and FDA DPA and was a postdoc fellow at UNC Chapel Hill.
With a strong background in protein biochemistry and bioconjungation, she has more than seven years of experience in the industry. Melissa holds a Ph.D. from the Wake Forest School of Medicine.
Scientist, ADC Process Development
Sowmyan joined MilliporeSigma's process and analytical development team in 2019. Before his current role, he optimized mAb downstream processes within the MSAT operations and developed novel processes for dairy proteins and lipids. He has six years of experience in industrial biotech and food science. Sowmyan holds an M.S. from the Ohio State University.
Senior Scientist Group Lead Process & Analytical Development
Jake has been with MilliporeSigma for 8 years, developing and manufacturing ADCs ranging from preclinical to commercial. During this time, he has developed, optimized, intensified, characterized, and scaled-up ADC processes.
Principal Scientist in Novel Modalities R&D
Haowei has been with MilliporeSigma for 5 years, first in process & analytical development, then in the novel modalities R&D department. He has more than 20 years of experience in analytical R&D, new product development, project management, technology transfer, and supporting GMP manufacturing cross academic and industry.
Ross Bemowski, Ph.D.
Associate Director of Analytical Development
Ross Bemowski oversees the analytical development for new API products coming out of the API R&D group located in Madison, WI. He is also the technical lead for Chetosensar™ technology platform. Prior to this, he was an analytical development scientist supporting the CDMO offering from our company.
He studied synthetic organometallic chemistry and received his Ph.D. from the University of Iowa.
Associate Director, ADC & Bioconjugation Services
Kaelyn is the associate director of ADC and Bioconjugation Services, leading the strategic marketing initiatives for the growing ADC CDMO landscape within the Life Science Services organization. Prior to joining the services business, she commercialized chemical biology products into the Sigma-Aldrich portfolio for early drug discovery research, including bioconjugation, probes, and targeted protein degradation.
Kaelyn received her B.S. in biochemistry at the University of St. Thomas, St. Paul, Minnesota, and her Ph.D. in chemical biology at Indiana University in Erin Carlson’s lab.
To continue reading please sign in or create an account.Don't Have An Account?